NGM BIOPHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | -1.28% |
|
-.--% | +79.28% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to NGM Bio's confere...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +79.28% | 129M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| -12.64% | 22.22B | |
| +0.44% | 22.27B | |
| -4.18% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +37.41% | 12.52B | |
| -23.95% | 8.34B |
- Stock Market
- Equities
- NGM Stock
- News NGM Biopharmaceuticals, Inc.
- Transcript : NGM Biopharmaceuticals, Inc. - Special Call